Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (Weighted Average) (2023 - 2025)

Monte Rosa Therapeutics' Shares Outstanding (Weighted Average) history spans 3 years, with the latest figure at $83.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding (Weighted Average) rose 12.4% year-over-year to $83.1 million; the TTM value through Dec 2025 reached $83.1 million, up 12.4%, while the annual FY2025 figure was $83.1 million, 12.4% up from the prior year.
  • Shares Outstanding (Weighted Average) reached $83.1 million in Q4 2025 per GLUE's latest filing, up from $82.4 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $83.1 million in Q4 2025 to a low of $49.3 million in Q1 2023.
  • Average Shares Outstanding (Weighted Average) over 3 years is $68.1 million, with a median of $72.6 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): skyrocketed 64.63% in 2024, then rose 0.47% in 2025.
  • A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $51.4 million in 2023, then soared by 43.8% to $73.9 million in 2024, then grew by 12.4% to $83.1 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Shares Outstanding (Weighted Average) are $83.1 million (Q4 2025), $82.4 million (Q3 2025), and $82.2 million (Q2 2025).